Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of “Buy” from Brokerages

Pliant Therapeutics, Inc. (NASDAQ:PLRXGet Free Report) has been assigned an average rating of “Buy” from the eleven analysts that are currently covering the company, Marketbeat reports. Eleven equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued a report on the stock in the last year is $48.50.

A number of analysts have recently commented on the company. Needham & Company LLC dropped their price objective on Pliant Therapeutics from $45.00 to $38.00 and set a “buy” rating for the company in a report on Monday. HC Wainwright lowered their price target on Pliant Therapeutics from $52.00 to $48.00 and set a “buy” rating for the company in a report on Monday. Wells Fargo & Company initiated coverage on Pliant Therapeutics in a report on Friday, December 8th. They issued an “overweight” rating and a $41.00 price target for the company. Leerink Partnrs reiterated an “outperform” rating on shares of Pliant Therapeutics in a report on Monday, October 16th. Finally, Royal Bank of Canada lowered their price target on Pliant Therapeutics from $54.00 to $53.00 and set an “outperform” rating for the company in a report on Friday, November 10th.

Check Out Our Latest Report on Pliant Therapeutics

Insider Buying and Selling at Pliant Therapeutics

In other news, insider Hans Hull sold 9,786 shares of the stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $17.23, for a total transaction of $168,612.78. Following the transaction, the insider now owns 185,069 shares of the company’s stock, valued at $3,188,738.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, General Counsel Mike Ouimette sold 5,197 shares of the firm’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $17.23, for a total transaction of $89,544.31. Following the transaction, the general counsel now owns 55,246 shares in the company, valued at $951,888.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Hans Hull sold 9,786 shares of the firm’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $17.23, for a total transaction of $168,612.78. Following the transaction, the insider now owns 185,069 shares in the company, valued at approximately $3,188,738.87. The disclosure for this sale can be found here. Insiders sold a total of 50,485 shares of company stock valued at $869,857 in the last ninety days. Insiders own 5.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. boosted its holdings in Pliant Therapeutics by 97.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,529 shares of the company’s stock worth $27,000 after buying an additional 754 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Pliant Therapeutics during the first quarter worth approximately $27,000. UBS Group AG boosted its holdings in Pliant Therapeutics by 18.4% during the second quarter. UBS Group AG now owns 3,537 shares of the company’s stock worth $28,000 after buying an additional 550 shares in the last quarter. US Bancorp DE boosted its holdings in Pliant Therapeutics by 144.3% during the second quarter. US Bancorp DE now owns 2,150 shares of the company’s stock worth $39,000 after buying an additional 1,270 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Pliant Therapeutics by 271.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,449 shares of the company’s stock worth $44,000 after purchasing an additional 1,790 shares during the period. Institutional investors and hedge funds own 97.30% of the company’s stock.

Pliant Therapeutics Trading Up 2.0 %

Shares of PLRX opened at $16.11 on Friday. The stock has a fifty day moving average of $16.92 and a two-hundred day moving average of $16.34. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.50 and a current ratio of 19.50. The company has a market capitalization of $964.99 million, a PE ratio of -5.77 and a beta of 1.19. Pliant Therapeutics has a fifty-two week low of $12.60 and a fifty-two week high of $32.90.

Pliant Therapeutics (NASDAQ:PLRXGet Free Report) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.08. Pliant Therapeutics had a negative return on equity of 32.50% and a negative net margin of 2,872.79%. As a group, analysts forecast that Pliant Therapeutics will post -2.88 EPS for the current year.

Pliant Therapeutics Company Profile

(Get Free Report

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

Read More

Analyst Recommendations for Pliant Therapeutics (NASDAQ:PLRX)

Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.